Anixa Biosciences, Inc.

Informe acción NasdaqCM:ANIX

Capitalización de mercado: US$88.8m

Anixa Biosciences Dirección

Dirección controles de criterios 3/4

El CEO de Anixa Biosciences es Amit Kumar , nombrado en Jul 2017, tiene una permanencia de 8.92 años. compensación anual total es $2.55M, compuesta por 32% salario y 68% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.79% de las acciones de la empresa, por valor de $1.59M. La antigüedad media del equipo directivo y de la junta directiva es de 8.9 años y 7.7 años, respectivamente.

Información clave

Amit Kumar

Chief Executive Officer (CEO)

US$2.5m

Compensación total

Porcentaje del salario del CEO32.01%
Permanencia del CEO8.9yrs
Participación del CEO1.8%
Permanencia media de la dirección8.9yrs
Promedio de permanencia en la Junta Directiva7.7yrs

Actualizaciones recientes de la dirección

Recent updates

Artículo de análisis • Mar 25

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Dec 19

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 40%?

Key Insights The projected fair value for Anixa Biosciences is US$4.21 based on 2 Stage Free Cash Flow to Equity Anixa...
Artículo de análisis • Sep 12

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Artículo de análisis • May 23

We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Artículo de análisis • Jan 19

We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Artículo de análisis • Oct 06

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Artículo de análisis • Apr 27

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Key Insights The projected fair value for Anixa Biosciences is US$7.24 based on 2 Stage Free Cash Flow to Equity Anixa...
Artículo de análisis • Jan 13

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Anixa Biosciences...
Artículo de análisis • Sep 26

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Aug 15

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

The shares of clinical-stage biotech Anixa Biosciences (NASDAQ:ANIX) jumped ~11% to reach the highest level since November on the announcement that the first patient received its chimeric antigen receptor T-cell (CAR-T) therapy in a Phase 1 clinical trial for ovarian cancer.   The dose escalation study conducted with its partner Moffitt Cancer Center is designed to assess the early efficacy data, safety and maximum tolerated dose of the follicle-stimulating hormone receptor T-cells. The trial is expected to enroll up to 48 patients at the Moffitt Cancer Center. Anixa’s (ANIX) CAR-T approach used in the study is known as chimeric endocrine receptor T-cell (CER-T) therapy. It differs from traditional CAR-T drugs in that it specifically targets the follicle-stimulating hormone receptor (FSHR) which, according to research, is exclusively located in ovarian cells of healthy adult women. In March, Anixa (ANIX) announced initial plans to conduct the trial.
Seeking Alpha • Jul 21

Anixa to get additional US patent linked to breast cancer vaccine technology

Anixa Biosciences (NASDAQ:ANIX) said the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent related to the company's breast cancer vaccine technology. The company said the technology has been exclusively licensed from and is being developed in partnership with Cleveland Clinic. The patent is titled 'Breast Cancer Vaccine' and the lead inventor is Vincent Tuohy of the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. "This breast cancer vaccine has the potential to prevent Triple Negative Breast Cancer ("TNBC"), the deadliest form of breast cancer, and perhaps other forms of breast cancer that express alpha-lactalbumin," said Anixa Chairman and CEO Amit Kumar.
Artículo de análisis • Jun 13

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • May 11

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June. While the biotech sector has been suffering large losses over the past month, Anixa Biosciences shares have moved up remarkably. Trial enrollment for the vaccine trial was fast, and the company seems optimistic about the near-term future of the company. The market is huge, and if the trial is successful, chances are we are seeing the beginning of a huge spike in share price. 2022 will, in any case, be the year for Anixa, with other programs ongoing as well.
Artículo de análisis • Feb 24

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Oct 28

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. By way of example, Anixa Biosciences...
Seeking Alpha • Sep 23

Our First Look At Anixa Biosciences

Today, we take an in-depth look at Anixa Biosciences, a small developmental firm on the west coast. The company's pipeline has multiple 'shots on goal' including one candidate that has shown some early analytical potential promise against the Covid-19 Delta variant. A full analysis is provided in the paragraphs below.
Artículo de análisis • Jun 12

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Artículo de análisis • Jan 13

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Amit Kumar en comparación con los beneficios de Anixa Biosciences?
FechaCompensación totalSalarioIngresos de la empresa
Apr 30 2026n/an/a

-US$10m

Jan 31 2026n/an/a

-US$10m

Oct 31 2025US$3mUS$815k

-US$11m

Jul 31 2025n/an/a

-US$11m

Apr 30 2025n/an/a

-US$12m

Jan 31 2025n/an/a

-US$12m

Oct 31 2024US$3mUS$785k

-US$13m

Jul 31 2024n/an/a

-US$12m

Apr 30 2024n/an/a

-US$12m

Jan 31 2024n/an/a

-US$11m

Oct 31 2023US$4mUS$720k

-US$10m

Jul 31 2023n/an/a

-US$11m

Apr 30 2023n/an/a

-US$11m

Jan 31 2023n/an/a

-US$12m

Oct 31 2022US$2mUS$631k

-US$14m

Jul 31 2022n/an/a

-US$14m

Apr 30 2022n/an/a

-US$16m

Jan 31 2022n/an/a

-US$15m

Oct 31 2021US$11mUS$573k

-US$13m

Jul 31 2021n/an/a

-US$11m

Apr 30 2021n/an/a

-US$9m

Jan 31 2021n/an/a

-US$10m

Oct 31 2020US$2mUS$522k

-US$10m

Jul 31 2020n/an/a

-US$10m

Apr 30 2020n/an/a

-US$9m

Jan 31 2020n/an/a

-US$9m

Oct 31 2019US$665kUS$476k

-US$12m

Compensación vs. Mercado: La compensación total de Amit($USD2.55M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD647.34K).

Compensación vs. Ingresos: La compensación de Amit ha sido consistente con los resultados de la empresa en el último año.

CEO

Amit Kumar (62 yo)

8.9yrs
Permanencia
US$2,546,684
Compensación

Dr. Amit Kumar, Ph.D. was a Director at Ascent Solar Technologies, Inc. since June 2007 until September 16, 2022 and had been its Independent Chairman of the Board since January 2011 until September 16, 20...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Amit Kumar
CEO, Chairman & Co-Chair of CBAB8.9yrsUS$2.55m1.79%
$ 1.6m
Michael Catelani
President9.6yrsUS$1.30m0.13%
$ 116.1k
Pamela Garzone
Chief Development Officer & Chair Breast Cancer Clinical Advisory Board4.8yrssin datossin datos
8.9yrs
Permanencia media
62yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de ANIX es experimentado (8.9 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Amit Kumar
CEO, Chairman & Co-Chair of CBAB13.6yrsUS$2.55m1.79%
$ 1.6m
Pamela Garzone
Chief Development Officer & Chair Breast Cancer Clinical Advisory Board3.3yrssin datossin datos
Lewis Titterton
Lead Independent Director8.9yrsUS$134.63k2.85%
$ 2.5m
H. Shepard
Member of Scientific Advisory Boardno datasin datossin datos
Linda Kelley
Member of Scientific Advisory Board7.7yrssin datossin datos
Ian Frazer
Member of Scientific Advisory Board6.7yrssin datossin datos
G. Budd
Member of Breast Cancer Clinical Advisory Board3.3yrssin datossin datos
Arnold Baskies
Member of SAB & Breast Cancer Clinical Advisory Board7.8yrsUS$134.63k0.40%
$ 352.4k
Marco Davila
Member of Scientific Advisory Board7.7yrssin datossin datos
Jose Conejo-Garcia
Member of Scientific Advisory Board7.7yrssin datossin datos
Daniel Abate-Daga
Member of Scientific Advisory Board7.7yrssin datossin datos
Emily Gottschalk
Independent Director6.7yrsUS$134.63k0.13%
$ 119.2k
7.7yrs
Permanencia media
73yo
Promedio de edad

Junta con experiencia: La junta directiva de ANIX se considera experimentada (7.7 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/06/17 12:59
Precio de las acciones al final del día2026/06/17 00:00
Beneficios2026/04/30
Ingresos anuales2025/10/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Anixa Biosciences, Inc. está cubierta por 6 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Andrew D'SilvaB. Riley Securities, Inc.
Jason KolbertD. Boral Capital LLC.
Ilya ZubkovFreedom Broker